The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Candriam S.C.A. significantly reduced its position in Becton, Dickinson and Company (BDX) by 33.7% during the third quarter. The institutional investor's remaining stake is now valued at approximately $2.87 million following the divestment. This reduction occurs as BDX transitions into a pure-play medical technology firm after spinning off its biosciences and diagnostics unit. Despite the institutional selling, the company reported robust financial results for the first quarter of fiscal year 2026. Management further signaled confidence by declaring a $1.05 per share dividend and authorizing a $10 million share repurchase program. The market impact remains mixed as strong corporate fundamentals and shareholder returns offset the pressure from institutional portfolio rebalancing.
Sign in to access this content
Sign In